Basel, Switzerland (PRWEB) May 22, 2013
Genedata, a leading provider of advanced software solutions for industrial biotechnology, drug discovery, and life science research, today announced AB Enzymes will use Genedata Selector™ as its bioinformatics platform for strain genome data management on all its production-relevant organisms. Genedata will provide AB Enzymes, one of the world’s oldest and best-known enzyme manufacturers, with a hosted solution of Genedata Selector accompanied by bioinformatics consulting services. Genedata Selector, an enterprise genome management solution, streamlines strain optimization and selection through highly automated strain comparison algorithms coupled with efficient data storage capabilities to further safeguard AB Enzymes intellectual property. The solution will serve as centralized data management system connecting AB Enzymes global R&D operations.
“As we look to advance our next-generation sequencing and strain optimization projects we need to integrate our genomics data management and data analysis processes. We looked for a bioinformatics solution that enables us to extract as much information as possible from all available data,” noted Dr. Jari Vehmaanperä, global R&D director at AB Enzymes. “In particular, we wanted a solution to help us better understand underlying genotype-phenotype relationships - Genedata Selector was the clear choice.”
Cost Savings - Time Efficiencies - IP Protection
Genedata Selector analyzes and manages all strain-related data in the context of strain optimization processes. Integrating genomic data with transcriptomics and metabolomics data, Genedata Selector improves gene functional annotation, and provides insights into molecular pathways. Based on sophisticated data analysis algorithms, Genedata Selector establishes genotype-phenotype relationships that enable researchers to efficiently select the most promising strain lines for production. With all experimental data systematically integrated in a single data management system, Genedata Selector supports standardized data analysis workflows across an entire organization. These capabilities contribute to significant cost and time savings while enabling researchers to focus on scientific questions versus manually handling complex data. Moreover, the solution’s intuitive and interactive visualization tools advance efficient decision-making and accelerate Genedata Selector’s time-to-value.
As a hosted solution, Genedata manages the entire Genedata Selector implementation and its ongoing maintenance and support, minimizing a company’s overhead and providing significant cost savings. Inherently efficient, flexible, and secure, the Genedata-hosted model:
“We are excited to add AB Enzymes, one of the world’s most successful enzyme companies, to our rapidly growing list of customers in the industrial biotechnology segment,” said Dr. Othmar Pfannes, CEO of Genedata. “AB Enzyme’s adoption of Genedata Selector validates our commitment to and investments in this vital and quickly evolving field. The combination of our domain expertise in bioinformatics and our unique Genedata Selector platform positions us to provide significant value for innovative partners such as AB Enzymes.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Read the full story at http://www.prweb.com/releases/AB_Enzymes/Strain_Optimization/prweb10730836.htm.
Copyright©2012 Vocus, Inc.
All rights reserved